Executive summary:
This investment memo discusses a new technology, namely the recombinant polypeptides called degradons, that selectively target and degrade disease-associated proteins. The technology has the potential to revolutionize the food, protein and agriculture industries, by developing new products and services that address the current and future needs of industrial partners, farmers, and consumers. Furthermore, the technology has the potential to catalyze economic and job growth in rural communities.

Core technology:
The degradon technology is a recombinant polypeptide comprising a target binding domain and a proteasome-binding domain. The technology is differentiated from current solutions on the market because it selectively targets and degrades disease-associated proteins, making it a potential game-changer in treating and preventing diseases.

Potential uses:
- Creating environmentally friendly animal feed through the selective degradation of plant proteins that are difficult to digest
- Developing novel crop protection technology by selectively targeting proteins that confer resistance to pests and diseases
- Enhancing the nutritive value of plant-based protein sources by selectively targeting specific proteins that diminish the digestibility of otherwise nutritious plant proteins
- Further applications in human and animal health, such as drug development and disease treatment.

Recommendation:
Further due diligence is warranted to explore the commercial potential of this technology. The potential applications in food, protein, and agriculture industries align with the firm’s mission to revolutionize these industries, and the potential to catalyze economic growth in rural communities aligns with the firm’s mission of generating significant returns for investors while doing good.

Sources:
- US Patent US11008372B2
- Google Patents: US11008372B2
- "Targeted Protein Degradation: A Rising Tide for Drug Discovery" - ACS Publications.